Kymera Therapeutics CEO Nello Mainolfi disposes of USD 3.39 million in common shares

• Kymera Therapeutics CEO Nello Mainolfi exercised options for 30,000 shares at $2.08 on Oct. 1, 2026.
• He sold 30,000 shares the same day at weighted average prices of $111.44 to $116.12.
• Directly held common stock fell to 666,568 shares.
• Directly held stock options decreased to 60,000 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-410839), on October 01, 2026, and is solely responsible for the information contained therein.